Analysis of Biocon's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
Description
INTRODUCTION
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
HIGHLIGHTS
Biocon's aspirations of expanding from its strong position in the Indian diabetes market were dashed when Pfizer pulled out of an insulin biosimilars deal in March 2012. It remains to be seen to what extent Biocon can continue development alone, or whether a replacement partner will be secured.
YOUR KEY QUESTIONS ANSWERED
See how Biocon already holds a strong position in its domestic insulin antidiabetics market, and a growing presence in the wider biosimilars field
Evaluate Biocon's marketing capabilities outside of India
Table of Contents
Table of Contents
ABOUT THIS REPORT
Chapter structure
Strategic insight
Product analysis
Operating performance
Company introduction
Data sourcing
Analyst consensus
PharmaVitae Explorer database
EXECUTIVE SUMMARY
Biocon biosimilars overview
Biocon biosimilars SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
STRATEGIC INSIGHT
Biocon to extend existing alliances and seek out new partners
Biocon to leverage in-house end-to-end development capabilities
KEY PRODUCTS
Overview
Biocon biosimilar portfolio
Basalog, insulin aspart, and insulin lispro
Overview
Insulin glargine, lispro, and aspart global market size
Key competitors
Biocon biosimilar development
Insugen (human insulin)
Overview
Insulin human market size
Key competitors
Biocon biosimilar development
Erypo (epoetin alfa)
Overview and market size
Key competitors
NUFIL and pegfilgrastim
Overview
Filgrastim and pegfilgrastim market size
Key competitors
Bmab-200 (trastuzumab)
Overview
Trastuzumab market size
Key competitors
Biocon biosimilar development
CORPORATE STRUCTURE
Background
Key corporate developments and company structure
Deals and alliances
Biocon and Pfizer conclude partnership
Biocon and Mylan
Biocon's other biosimilar-related deals
Recent developments
APPENDIX
References
Datamonitor reports
Exchange rates
TABLES
Table: Biocon - biosimilar and novel biologic portfolio
Table: Forecasted lispro, aspart, and glargine insulin sales in the seven major markets and ROW ($m), 2011-16
Table: Biosimilar insulin aspart, insulin glargine, and insulin lispro products currently launched or in development
